Eli Lilly's $0.9 billion acquisition of Adverum Biotechnologies enters its final tender window this week, with the Redwood City clinical-stage firm issuing final reminders to remaining stockholders. The deal, announced in October, values Adverum at approximately $10.50 per share—a 75% premium to the thirty-day VWAP preceding announcement. The tender offer expires December 5, 2025 at 11:59 PM Eastern.

Adverum brings Lilly a platform in intravitreal gene therapy, specifically AAV-based treatments for retinal disease. The company's lead asset, ADVM-062, is a single-injection therapy candidate for wet age-related macular degeneration currently in Phase II trials with twelve-month durability data. Lilly simultaneously gains manufacturing infrastructure in viral vector production and a clinical team that has navigated FDA dialogue on ocular gene therapy dosing—expertise absent from Lilly's existing ophthalmology franchise. The transaction also eliminates a potential competitor in the $8 billion anti-VEGF market, where Lilly has no approved therapy but faces Regeneron's Eylea dominance.

The timing matters for three reasons. First, Lilly closes this deal as its GLP-1 franchise generates $13 billion in trailing cash flow, creating unusual bandwidth for speculative bets in non-core therapeutic areas. Second, the FDA is expected to issue updated gene therapy guidance in Q1 2026, and owning the asset pre-guidance locks in clinical pathway optionality. Third, Adverum's cash burn rate of approximately $90 million annually was projected to exhaust runway by mid-2026, making this the final window for a premium exit before dilutive financing. Lilly pays for the platform, not the desperation.

Allocators should watch three follow-on events. First, the tender close and subsequent delisting, expected by December 12, which will reveal final participation rates and any residual activist positions. Second, Lilly's Q4 earnings commentary in early February, where management typically flags integration priorities and R&D reallocation—watch for mentions of ocular pipeline expansion or manufacturing capex. Third, any pre-IND filings for next-generation AAV constructs in Q1 2026, which would signal Lilly's intent to accelerate beyond ADVM-062 into broader retinal indications.

Lilly's deal flow over the past eighteen months now includes $2.4 billion in clinical-stage platform acquisitions, with gene therapy, radiopharmaceuticals, and precision oncology representing the pattern. The Adverum close removes one of the last independent intravitreal gene therapy platforms from public markets.